Literature DB >> 21769491

ISN/RPS 2003 class II mesangial proliferative lupus nephritis: a comparison between cases that progressed to class III or IV and cases that did not.

Seung Geun Lee1, Yong Mee Cho, Min Wook So, Sung Soo Kim, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo.   

Abstract

Lupus nephritis (LN) class II has generally been considered a mild form of LN with a good response to treatment. Although the number was small, there have also been reports on later progression to class III or IV, resulting in poor renal and patient outcome. This study aims to review cases of LN class II to analyze differences between cases that progressed to class III or IV and cases that did not. We retrospectively analyzed 15 cases of LN class II among 277 cases of biopsy-proven lupus nephritis diagnosed in a tertiary medical center over about 14 years. Among the 15 patients, 5 patients progressed to class III or IV. Biopsy specimens were reviewed by a pathologist according to the ISN/RPS 2003 classification. Response to treatment was evaluated at 6 months after treatment. On fluorescence microscopy (IF), there was significantly higher degree of deposition in the glomeruli of IgM, IgA and C4 in the progression group than in the non-progression group. At 6 months after treatment, there was a trend toward higher rates of complete remission in the non-progression group (90%) compared with those in the progression group (40%, p = 0.077). Five of the 15 cases of ISN/RPS 2003 class II glomerulonephritis progressed to class III or IV over a mean of 5 years. The degree of immune-complex deposition for IgM, IgA and C4 in the glomeruli was significantly higher in the progression group.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21769491     DOI: 10.1007/s00296-011-1986-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  15 in total

1.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

2.  Progression of mesangial and focal to diffuse lupus nephritis.

Authors:  E M Ginzler; A D Nicastri; C K Chen; E A Friedman; H S Diamond; D Kaplan
Journal:  N Engl J Med       Date:  1974-10-03       Impact factor: 91.245

3.  Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure.

Authors:  Mikkel Faurschou; Henrik Starklint; Poul Halberg; Søren Jacobsen
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

Review 4.  Mesangial lupus nephritis with associated nephrotic syndrome.

Authors:  N Stankeviciute; W Jao; A Bakir; J P Lash
Journal:  J Am Soc Nephrol       Date:  1997-07       Impact factor: 10.121

5.  A new morphologic index for the evaluation of renal biopsies in lupus nephritis.

Authors:  G S Hill; M Delahousse; D Nochy; E Tomkiewicz; P Rémy; F Mignon; J P Méry
Journal:  Kidney Int       Date:  2000-09       Impact factor: 10.612

6.  Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis.

Authors:  C C Najafi; S M Korbet; E J Lewis; M M Schwartz; M Reichlin; J Evans
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

7.  Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study.

Authors:  Peter N Furness; Nick Taub
Journal:  Am J Surg Pathol       Date:  2006-08       Impact factor: 6.394

8.  Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome.

Authors:  H A Austin; L R Muenz; K M Joyce; T T Antonovych; J E Balow
Journal:  Kidney Int       Date:  1984-04       Impact factor: 10.612

9.  Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group.

Authors:  R P Sloan; M M Schwartz; S M Korbet; R Z Borok
Journal:  J Am Soc Nephrol       Date:  1996-02       Impact factor: 10.121

Review 10.  The classification of glomerulonephritis in systemic lupus erythematosus revisited.

Authors:  Jan J Weening; Vivette D D'Agati; Melvin M Schwartz; Surya V Seshan; Charles E Alpers; Gerald B Appel; James E Balow; Jan A Bruijn; Terence Cook; Franco Ferrario; Agnes B Fogo; Ellen M Ginzler; Lee Hebert; Gary Hill; Prue Hill; J Charles Jennette; Norella C Kong; Philippe Lesavre; Michael Lockshin; Lai-Meng Looi; Hirofumi Makino; Luiz A Moura; Michio Nagata
Journal:  Kidney Int       Date:  2004-02       Impact factor: 10.612

View more
  6 in total

1.  [Lupus nephritis].

Authors:  S Melderis; T Wiech; C Iking-Konert; O M Steinmetz
Journal:  Z Rheumatol       Date:  2018-09       Impact factor: 1.372

2.  Long-term renal outcomes of mesangial proliferative lupus nephritis in Chinese patients.

Authors:  Shaofan Wang; Duqun Chen; Ke Zuo; Feng Xu; Weixin Hu
Journal:  Clin Rheumatol       Date:  2021-09-22       Impact factor: 2.980

Review 3.  Mesangial cell-specific antibodies are central to the pathogenesis of lupus nephritis.

Authors:  Guillaume Seret; Yannick Le Meur; Yves Renaudineau; Pierre Youinou
Journal:  Clin Dev Immunol       Date:  2011-11-28

Review 4.  Classifying lupus nephritis: an ongoing story.

Authors:  Saba Kiremitci; Arzu Ensari
Journal:  ScientificWorldJournal       Date:  2014-12-08

5.  Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis.

Authors:  Maria Victoria Collado; Enrique Dorado; Silvia Rausch; Graciela Gomez; Marina Khoury; Federico Zazzetti; María Gargiulo; Lorena Suarez; Rafael Chaparro; Sergio Paira; Laura Galvan; Vicente Juarez; Cecilia Pisoni; Mercedes Garcia; Liliana Martinez; Analia Alvarez; Clarisa Alvarez; Juan Barreira; Judith Sarano
Journal:  J Clin Rheumatol       Date:  2016-09       Impact factor: 3.517

6.  Lupus nephritis progression in FcγRIIB-/-yaa mice is associated with early development of glomerular electron dense deposits and loss of renal DNase I in severe disease.

Authors:  Kjersti Daae Horvei; Hege Lynum Pedersen; Silje Fismen; Dhivya Thiyagarajan; Andrea Schneider; Ole Petter Rekvig; Thomas H Winkler; Natalya Seredkina
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.